Fortress Biotech (FBIOP) EBITDA Yield: History & Chart

Fortress Biotech, Inc.(FBIOP)

Biotechnology · Bay Harbor Islands, FL

$17.75-0.35 (-1.93%)

Delayed quote: Oct 6, 2026, 10:53 AM EDT

About Fortress Biotech, Inc.

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Bay Harbor Islands, FL

78 employees

www.fortressbiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lindsay A. Rosenwald

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Fortress Biotech, Inc. (FBIOP)	$139.73M	N/A	N/A	N/A	N/A
Immuneering Corporation (IMRX)vs ›	$139.95M	N/A	N/A	N/A	N/A
Alpha Cognition Inc (ACOG)vs ›	$138.31M	N/A	N/A	N/A	N/A
Sutro Biopharma, Inc. (STRO)vs ›	$141.82M	N/A	N/A	N/A	N/A
Protara Therapeutics, Inc. (TARA)vs ›	$142.48M	N/A	2.27%	2.27%	2.27%
KORU Medical Systems, Inc. (KRMD)vs ›	$136.65M	N/A	0.23%	1.76%	3.40%
Nyxoah S.A. (NYXH)vs ›	$143.10M	N/A	N/A	N/A	N/A
Atrium Therapeutics, Inc. (RNA)vs ›	$135.65M	N/A	N/A	N/A	N/A
Korsana Biosciences, Inc. (KRSA)vs ›	$144.19M	N/A	N/A	N/A	N/A
Freenome, Inc. (FRNM)vs ›	$135.08M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Fortress Biotech, Inc. (FBIOP)

$139.73M

N/A

Immuneering Corporation (IMRX)vs ›

$139.95M

N/A

Alpha Cognition Inc (ACOG)vs ›

$138.31M

N/A

Sutro Biopharma, Inc. (STRO)vs ›

$141.82M

N/A

Protara Therapeutics, Inc. (TARA)vs ›

$142.48M

N/A

2.27%

KORU Medical Systems, Inc. (KRMD)vs ›

$136.65M

N/A

0.23%

1.76%

3.40%

Nyxoah S.A. (NYXH)vs ›

$143.10M

N/A

Atrium Therapeutics, Inc. (RNA)vs ›

$135.65M

N/A

Korsana Biosciences, Inc. (KRSA)vs ›

$144.19M

N/A

Freenome, Inc. (FRNM)vs ›

$135.08M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

FBIOP EBITDA Yield Metrics

FBIOP Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics